Around 100 new cancer drugs, defined as new molecular entities, were approved in China between 2005 and 2021. More than half of these new cancer drugs do not constitute innovations in mechanism of action or therapy and do not have documented meaningful clinical benefit. Approaches are needed to promote meaningful innovation for patients with cancer.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Kesselheim, A. S. & Avorn, J. The most transformative drugs of the past 25 years: a survey of physicians. Nat. Rev. Drug Discov. 12, 425–431 (2013).
Center for Drug Evaluation. National Medical Products Administration. Annual Drug Evaluation Report https://www.cde.org.cn/main/news/viewInfoCommon/f92b7bdf775bbf4c4dc3a762f343cdc8 (2021).
Zhang, Y. et al. Overall survival benefits of cancer drugs approved in China from 2005 to 2020. JAMA Netw. Open 5, e2225973 (2022).
Li, G., Qin, Y., Xie, C., Wu, Y. L. & Chen, X. Trends in oncology drug innovation in China. Nat. Rev. Drug Discov. 20, 15–16 (2021).
Kesselheim, A. S., Wang, B. & Avorn, J. Defining “innovativeness” in drug development: a systematic review. Clin. Pharmacol. Ther. 94, 336–348 (2013).
Aronson, J. K., Ferner, R. E. & Hughes, D. A. Defining rewardable innovation in drug therapy. Nat. Rev. Drug Discov. 11, 253–254 (2012).
Olivier, T., Haslam, A. & Prasad, V. Anticancer drugs approved by the US Food and Drug Administration from 2009 to 2020 according to their mechanism of action. JAMA Netw. Open 4, e2138793 (2021).
Hwang, T. J., Ross, J. S., Vokinger, K. N. & Kesselheim, A. S. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ 371, m3434 (2020).
Naci, H., Carter, A. W. & Mossialos, E. Why the drug development pipeline is not delivering better medicines. BMJ 351, h5542 (2015).
Fojo, T., Mailankody, S. & Lo, A. Unintended consequences of expensive cancer therapeutics — the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol. Head Neck Surg. 140, 1225–1236 (2014).
Munos, B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959–968 (2009).
Center for Drug Evaluation. National Medical Products Administration. Guidance on Clinical Value-Oriented Oncology Drug Research and Development https://www.cde.org.cn/main/news/viewInfoCommon/ef7bfde96c769308ad080bb7ab2f538e (2021).
Liu, A. Is China’s drug regulator suddenly raising the bar on cancer med R&D? Not exactly, say experts. Fierce Pharma https://www.fiercepharma.com/pharma-asia/china-s-drug-regulator-suddenly-raising-bar-cancer-med-r-d-not-exactly-say-experts (2021).
National Medical Products Administration. Regulations for the Implementation of the Drug Administration Law (Draft) https://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20220509220456183.html (2022).
The authors thank H. Naci and L. Shi for insightful review and comments on this work, and Y. Li for assistance with data processing. X.G. gratefully acknowledges grants from Research on Equitable Access and Rational Use of Medicines sponsored by Peking University Health Science Center. The funding organization had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No other disclosures were reported.
The authors declare no competing interests.
About this article
Cite this article
Zhang, Y., Wagner, A.K. & Guan, X. Newly approved cancer drugs in China — innovation and clinical benefit. Nat Rev Clin Oncol (2023). https://doi.org/10.1038/s41571-023-00728-3